Copertina

Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Marina Nasrin Sharifi, Erika Heninger, Matthew Leeson Bootsma, Emma Elizabeth Recchia, Matthew Thomas Breneman, Amy Kristine Taylor, Shuang George Zhao, Aaron Matthew LeBeau, David Kosoff
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Evaluation of Second‐Line Treatment for Castration‐Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors
di: Kazuro Kikkawa, et al.
Pubblicazione: (2024)

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
di: Kazuma Yukihiro, et al.
Pubblicazione: (2026)

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study
di: Himawari Asanuma, et al.
Pubblicazione: (2026)

Therapeutic Exhaustion After Upfront Androgen Receptor Signaling Inhibitor: A Hidden Determinant of Post‐CRPC Survival
di: Shengyi Chen, et al.
Pubblicazione: (2026)

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
di: Mitsuhisa Nishimoto, et al.
Pubblicazione: (2025)

Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer
di: Yu‐Hsiang Lin, et al.
Pubblicazione: (2025)

RETRACTION: Interleukin‐4 Activates Androgen Receptor Through CBP/p300
Pubblicazione: (2025)

pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
di: Piotr Bialas, et al.
Pubblicazione: (2024)

Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis
di: Marco Oderda, et al.
Pubblicazione: (2024)

Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey‐Holden Prostate Cancer Academy Meeting
di: Tanya Stoyanova, et al.
Pubblicazione: (2025)

Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics
di: Kristofer G. Taylor, et al.
Pubblicazione: (2026)

Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
di: Masanori Ishida, et al.
Pubblicazione: (2025)

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High‐Risk Prostate Cancer
di: Hanyang Tao, et al.
Pubblicazione: (2024)

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target
di: Jacky T. F. Luk, et al.
Pubblicazione: (2026)

Impact of Testosterone Recovery on Oncologic Outcomes in High‐Risk, Localized Prostate Cancer
di: Trevor C. Hunt, et al.
Pubblicazione: (2025)

Outcome Differences Between Subgroups of Favorable Intermediate Risk Prostate Cancer After Radical Prostatectomy
di: Matthew T. Steidle, et al.
Pubblicazione: (2026)

Long‐Term Follow‐Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial
di: Braden Millan, et al.
Pubblicazione: (2025)

Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy
di: Cem Onal, et al.
Pubblicazione: (2026)

Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients
di: Cem Onal, et al.
Pubblicazione: (2024)

Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
di: Hyun‐Kyung Ko, et al.
Pubblicazione: (2025)

The Mediterranean Diet and Benign Prostatic Hyperplasia: A Pathway to Improved Urinary Health
di: İsa Dağlı, et al.
Pubblicazione: (2025)

Altered Ten Eleven Translocation Methylcytosine Dioxygenase Expression and DNA Hydroxymethylation in a Mouse Model of Prostate Cancer
di: Matthew Aguilera, et al.
Pubblicazione: (2025)

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer
di: William Lautert‐Dutra, et al.
Pubblicazione: (2026)

LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via the p53 Signaling Pathway
di: Zhe Tang, et al.
Pubblicazione: (2025)

Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
di: Elizabeth Robinson, et al.
Pubblicazione: (2025)

Influence of 5‐Alpha Reductase Inhibitors on PI‐RADS Scores and Prostate Cancer Detection: A Systematic Review and Meta‐Analysis
di: Lian Qiong, et al.
Pubblicazione: (2025)

Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review
di: Mark Willy L. Mondia, et al.
Pubblicazione: (2025)

Significant Effect of Carbon‐Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High‐Risk Prostate Cancer Patients: A Two‐Center Controlled Trial Compare With X‐Ray External Beam Radiation Therapy
di: Xue Zhao, et al.
Pubblicazione: (2024)

A Gene Expression Tumor Signature Optimizing Partial Area‐Under‐the‐Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer
di: Travis A. Gerke, et al.
Pubblicazione: (2026)

In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines
di: Ana Laura Gómez-Rosas, et al.
Pubblicazione: (2026)

RETRACTION: Lin28 Induces Resistance to Anti‐Androgens via Promotion of AR Splice Variant Generation
Pubblicazione: (2026)

Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways
di: Nibrass Taher Abdali, et al.
Pubblicazione: (2025)

c‐Kit‐Mediated PI3K/AKT and Wnt/β‐Catenin Signaling Drives Resistance to 5α‐Reductase Inhibitors in Benign Prostatic Hyperplasia
di: Jun Zhu, et al.
Pubblicazione: (2025)

Do Prostate Imaging‐Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes?
di: Kyle Tsai, et al.
Pubblicazione: (2024)

Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study
di: Giulio Bevilacqua, et al.
Pubblicazione: (2025)

Enhancing Diagnostic Accuracy in Prostate Oncology: A Multidimensional Perspective on Prostate Specific Antigen Density
di: Shengyi Chen, et al.
Pubblicazione: (2025)

Safety and Efficacy of Bipolar Transurethral Vaporization of the Prostate and Bipolar Transurethral Resection of the Prostate in the Management of Large Volume Benign Prostatic Hyperplasia: A Prospective Randomized Study
di: Amr M. Lotfy, et al.
Pubblicazione: (2026)

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
di: Yifu Shi, et al.
Pubblicazione: (2025)

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
di: Tatsuya Shimomura, et al.
Pubblicazione: (2026)

Discovering the Prostate: Notes on History and Historiography
di: Diederik F. Janssen
Pubblicazione: (2025)